Tag Archives: Latent viral reactivation

RA drug warning for active or latent HCV carriers

A new Pfizer drug marketed as Xeljanz (tofacitinib) is “a prescription medicine called a Janus kinase (JAK) inhibitor. XELJANZ is used to treat adults with moderately to severely active rheumatoid arthritis in which methotrexate did not work well. It is … Continue reading

Posted in Blood info, Guest authors, HCV Health, HCV Risks (documented), Medical News, VA Health Care | Tagged , , , , , | 9 Comments